GLP-1s in Hip and Knee Arthroplasty

Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-90
SponsorNova Scotia Health Authority

About this trial

The number of people living with hip and knee arthritis continues to grow. A large amount of these people are also overweight and diagnosed with obesity. Obesity leads to more stress on hip and knee joints, causing them to wear out sooner. This process is called arthritis. When arthritis gets worse, the joints often need to be replaced due to pain and poor mobility. Very heavy patients often have other health problems that can impair the ability to manage arthritis. Excess weight and health problems can change the way heavy patients recover after surgery, leading to a greater risk of complications. A new type of medicine might be able to improve how obese patients manage their hip and knee pain, as well as improve outcomes after surgery. This type of medicine is called a GLP-1. Investigators will study 2 groups, with one receiving the medicine while the other does not. The goal is to understand how these medications work in the time leading up to surgery and in the early postoperative recovery phase. If these medications help, it may improve the care of high risk obese patients.

Eligibility criteria

Qualifiers

Patients with a diagnosis of hip or knee arthritis and are a deemed candidate for THA or TKA by an orthopaedic surgeon

Diagnosis of BMI 35+ with an obesity-related health condition (Coronary vascular disease, previous stroke, type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, asthma) or BMI 40+

Patients must be between 18-90 years of age

Able to provide informed consent

Disqualifiers

Cognitive impairment that precludes study participation and compliance

Patients unwilling to undergo smoking cessation prior to surgery

Patients currently taking biologic medications that suppress the immune system

Patients currently taking GLP-1 medications

Trial design

Treatments tested in this trial

  • GLP-1 Receptor Agonists + Behavioral modification
  • Behavioral + placebo

Treatment groups

100 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Nova Scotia Health Authority

Lead sponsor

Orthopaedic Innovation Centre

Collaborator

Dalhousie University

Collaborator

University of Manitoba

Collaborator